The U.S. House of Representatives has approved an amendment directing the Department of Veterans Affairs to evaluate how its healthcare system can be adapted to incorporate psychedelic therapies for veterans with PTSD and substance use disorders.
Dried psilocybin mushrooms (left) and MDMA tablets (right).
Filed by Representative Lou Correa (D-CA), the measure was added to the Military Construction, Department of Veterans Affairs, and Related Agencies spending package. The amendment instructs the VA to assess what changes would be necessary to integrate federally approved psychedelic treatments into its healthcare infrastructure, should such therapies gain regulatory approval.
Specifically, the amendment mandates that the VA examine how to implement provider training and supervision programs and establish pilot programs to inform clinical integration of these therapies. It also calls for recommendations on how to support the rollout of such treatments across VA medical facilities.
Correa has long advocated for expanded mental health options for veterans, including exploring the therapeutic potential of psychedelics like MDMA and psilocybin. Numerous studies in recent years have suggested that these substances, when administered in clinical settings, may offer significant benefits for individuals struggling with post-traumatic stress and addiction.
The full appropriations bill is expected to receive a final House vote this week.
